Carey K. Anders, MD, Duke Cancer Institute

Carey K. Anders, MD, discusses lessons learned from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Dr. Anders on Leveraging ADCs in Metastatic TNBC

December 8th 2021

Carey K. Anders, MD, discusses leveraging antibody-drug conjugates in the treatment of patients with metastatic triple-negative breast cancer.

Impact of Recent Clinical Data on Treatment for HER2+ MBC

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Treatment Choice for Patient Relapsing With Brain Metastases

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2CLIMB: Brain Metastases Data

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early-Stage Breast Cancer

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Guidelines and Approaches to HER2 Testing for Breast Cancer

Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases

Carey K. Anders, MD, Duke Cancer Institute;Sarah L. Sammons, MD

June 5th 2020

Collectively, there are more options than ever in the space of HER2-positive breast cancer brain metastases, a significant advance for our hundreds and thousands of patients facing this challenging disease.

Carey K. Anders, MD, Duke Cancer Institute

Articles

Latest Updated Articles

Latest Conference Coverage